The damaging variants in SAMHD1 that we identified are associated with increased risk of ‘all cancer’ in men and women, as well as in sex-specific cancers, highlighting SAMHD1 as a novel risk factor for prostate cancer in men and hormone-sensitive cancers in women. This evidence concerns the gene SAMHD1 and prostate cancer.